Glomerular Disease Study & Trial Consortium

Name

Glomerular Disease Study & Trial Consortium

Legal name

GlomCon Foundation

Website

https://glomcon.org

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Nephrology Medical Education and Research

NAICS

Voluntary Health Organizations (813212), Other Schools and Instruction (6116)

SIC

Services-Social Services (8300)

akta.pro primary industry

Glomerular & Autoimmune Kidney Disease (Glomerulonephritis) Clinics (HLAKAHAG)

akta.pro secondary industries

Nephrology Telemedicine Platforms (HLALAGAI), Genetic & Rare Kidney Disease Clinics (HLAKAHAO)

Keywords

• Kidney disease education
• Nephrology research consortium
• Clinical fellowship programs
• Medical education seminars
• Glomerular disease trials

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Educational Grants: The organization receives educational grants from pharmaceutical companies including Travere Therapeutics, Vertex Pharmaceuticals, Novartis, Otsuka, Calliditas, and Apellis to fund educational programs such as the Emerging Therapeutics series
2. Corporate Membership/Sponsorship: Corporate supporters provide ongoing financial support enabling the organization to pursue its mission, as acknowledged on the supporter page
3. Donations: Tax-deductible donations from supporters used to maintain web infrastructure, online educational platforms, and IT systems

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

Core offering

GlomCon is a nonprofit consortium that delivers glomerular kidney disease education and research services through weekly live seminars, multi-track clinical fellowship programs, a kidney disease patient registry, a clinical trials platform, peer-reviewed publications (GlomCon Pubs and RKD Journal), the GlomPedia mobile reference app, and the GlomCon Network clinician community. Its audiences include nephrologists, nephropathologists, researchers, trainees, patients with glomerular disease, and sponsoring life-sciences organizations worldwide.

Product overview

GlomCon Foundation is a mission-driven nonprofit organization that provides a comprehensive suite of interconnected educational, research, and patient support programs for glomerular diseases. The core offerings include weekly GlomCon Seminars and a Virtual Glomerular Disease Fellowship for clinician education; GlomCon Pubs and RKD Journal for academic publishing; the Emerging Therapeutics program for drug information; Clinical Trials Platform and multi-site Real-World Evidence Studies for research; the GlomCon Network community platform and Patient Portal for engagement; GlomPedia mobile app for patient education; and the Kidney Disease Registry for data collection. Regional programs serve Ibero-Latinoamerica, Portugal, Ghana, China, Philippines, and Arabia. The organization also coordinates the Centers of Excellence initiative to establish standards for glomerular disease care globally.

Differentiator

Problem solved

Functional benefit

Brands

• GlomPedia: A mobile application available on Apple App Store and Google Play providing kidney disease education resources.
• NephroVax
• GlomCon Pubs
• GlomCon Network
• EMBARK Awareness
• GlomCon ILA (Ibero-Latinoamérica)
• GlomCon Foundation Virtual Glomerular Disease Fellowship
• MyGlomCon
• Kidney Disease Registry
• RKD Journal

Products and services

• GlomCon Weekly Seminars

Quantifiable outcome

• Over 550 nephrologists have graduated from GlomCon fellowship programs since 2020, with many launching new glomerular disease clinics and participating in clinical trials
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• American Kidney FundcoreStrategic or Co-development Partner · 5 May 2025GlomCon Foundation, American Kidney Fund, and IgA Nephropathy Foundation announced a landmark collaboration to develop a consensus framework for Centers of Excellence in Glomerular Disease Care, convening over 50 representatives from leading academic and research institutions.
• IgA Nephropathy FoundationcoreStrategic or Co-development Partner · 5 May 2025Partnering with GlomCon Foundation and American Kidney Fund to develop consensus framework for Centers of Excellence in Glomerular Disease Care, focusing on clinical expertise, research, education, and patient-centered care.
• Baim Institute for Clinical ResearchcoreStrategic or Co-development Partner · 6 June 2024GlomCon Foundation and Baim Institute for Clinical Research entered a formal research collaboration agreement to leverage complementary strengths for supporting design and implementation of large real-world evidence studies, global registries, and randomized controlled trials. The Baim Institute brings expertise in clinical trial design and management, while GlomCon contributes glomerular disease expertise and its global expert network.
• IgA Nephropathy FoundationcoreGTM or Marketing PartnerThe IgA Nephropathy Foundation has created a community for patients living with IgA Nephropathy and their caregivers. GlomCon partners to provide educational content and resources for the patient community.
• Travere TherapeuticsminorOthersCorporate supporter providing educational grants for the Emerging Therapeutics program. Travere is the manufacturer of Filspari (sparsentan) for IgA nephropathy.
• NovartisminorOthersCorporate supporter providing educational grants for glomerular disease education programs.
• Vertex PharmaceuticalsminorOthersCorporate supporter providing educational grants for the Emerging Therapeutics program, particularly related to APOL1-mediated kidney disease.
• OtsukaminorOthersCorporate supporter providing educational grants for glomerular disease education.
• CalliditasminorOthersCorporate supporter providing educational grants for glomerular disease education.
• ApellisminorOthersCorporate supporter providing educational grants for glomerular disease education.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• NephCure Kidney International: A nonprofit focused on nephrotic syndrome, FSGS, and rare glomerular diseases — directly overlapping with GlomCon's glomerular disease niche. Comparable in supporting patient communities, physician education, and research funding for the same disease areas.
• Alport Syndrome Foundation: A nonprofit focused on Alport syndrome — a rare hereditary glomerular disease. Comparable as a nonprofit addressing a specific rare glomerular disease with patient education, research funding, and physician engagement programs.
• American Kidney Fund: A nonprofit providing kidney disease patient financial assistance, education, and professional resources. Directly comparable as a kidney-focused nonprofit that recently partnered with GlomCon on the Centers of Excellence initiative, and overlaps in serving patients, clinicians, and supporting research.
• IgA Nephropathy Foundation: A patient-focused nonprofit dedicated to IgA nephropathy, partnering with GlomCon on educational content and the Centers of Excellence framework. Directly comparable as a kidney-disease nonprofit with overlapping mission in education, research collaboration, and patient community support.

Broad incumbents

• European Renal Association (ERA): The leading European professional society for nephrology, providing congresses, journals (NDT), and educational programming. Comparable as a global nephrology education and research organization with significant overlap in glomerular disease content, though with a broader and European-centric mandate.
• American Society of Nephrology: The premier U.S. professional society for nephrologists, providing continuing education, journals (JASN), and clinical research platforms like NKF-KDOQI. Highly comparable as a nephrology education and research organization, but with broader scope and significantly larger institutional resources.
• National Kidney Foundation: The largest U.S. nonprofit dedicated to kidney disease awareness, prevention, and treatment. Comparable as a kidney-focused nonprofit that combines patient education, professional education, and research funding, but operates across all kidney diseases rather than specializing in glomerular disease.

Regional players

• Kidney Foundation of Canada: The leading Canadian nonprofit for kidney disease, providing patient education, research funding, and professional resources. Comparable as a kidney-disease nonprofit with overlapping mission, though it primarily serves a Canadian audience rather than GlomCon's global physician focus.
• PKD Foundation: The leading nonprofit dedicated to polycystic kidney disease (PKD), funding research and providing patient education. Comparable in structure and mission as a rare kidney-disease nonprofit, though it focuses on PKD rather than glomerular diseases.

Others

• Baim Institute for Clinical Research: A clinical research organization partnering with GlomCon on real-world evidence studies, registries, and randomized trials. Comparable as an adjacent collaborator rather than direct competitor — both organizations support clinical research infrastructure in nephrology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GlomCon
• YouTubeyoutube.com/@glomcon
• Facebookfacebook.com/glomcon
• LinkedInlinkedin.com/company/glomerular-disease-study-trial-consortium
• Instagraminstagram.com/glomcon

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glomerular Disease Study & Trial Consortium